ARTICLE | Clinical News

Imbruvica: Ph II PCYC-1121 data

December 30, 2016 10:06 PM UTC

The open-label, international Phase II PCYC-1121 trial in 60 patients with relapsed or refractory marginal zone lymphoma showed that once-daily 560 mg Imbruvica led to an ORR of 48%, including 2 complete responses and 27 partial responses, at a median follow-up of 19.4 months. Median PFS was 14.2 months and the 18-month PFS rate was 62%. Median duration of response and OS were not reached. Data were presented at the American Society of Hematology meeting in San Diego...

BCIQ Company Profiles

AbbVie Inc.

Johnson & Johnson

BCIQ Target Profiles

Bruton's tyrosine kinase (Btk)